Dysglycemia and Cardiometabolic Risk: Pathophysiological Rationale and the Emerging Role of Nutraceuticals in Integrated Prevention - PubMed

4 hours ago

Dysglycemia is an early stage of cardiometabolic disease marked by insulin resistance (IR), metabolic inflammation, and increased cardiovascular risk.
Its high prevalence and asymptomatic nature often lead to delayed diagnosis and treatment, missing early intervention opportunities.
Nutraceuticals are emerging as supportive tools for managing dysglycemia, especially in individuals not yet needing pharmacological therapy.
Key mechanisms targeted by nutraceuticals include impaired insulin sensitivity, oxidative stress, chronic inflammation, and altered postprandial glucose metabolism.
Clinical evidence supports the use of micronutrients, polyphenols, and plant extracts like Mangifera indica, Momordica charantia, and Malus domestica for glycemic control.
These phytocomplexes modulate carbohydrate absorption, enhance glucose uptake, stimulate incretin secretion, and improve endothelial function.
When combined with lifestyle changes, nutraceuticals can reduce glycemic variability, improve metabolic resilience, and delay type 2 diabetes progression.
Nutraceuticals serve as a bridge between lifestyle measures and pharmacological treatment in personalized dysglycemia management.

Hasty Briefsbeta